Leerink maintains Outperform on Arcturus Therapeutics; sets $19 target
Leerink Partners reiterated an Outperform rating on Arcturus Therapeutics and kept a $19.00 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.